In immunocompetent mouse models for breast and ovarian cancer, treatment with DNMTi has been correlated with increases in PD-1 or CTLA-4 checkpoint proteins, necessitating combinatorial treatment with checkpoint inhibitors despite increased expression of ERVs, anti-viral response genes and antigen presentation machinery (14, 25, 61). This evidence concerns the gene CTLA4 and ovarian carcinoma.